Fig. 1: Trial profile.
Eligible patients were treated with three cycles of neoadjuvant therapy comprising serplulimab, carboplatin, and albumin paclitaxel every 21 days, followed by surgical resection.
Fig. 1: Trial profile. | Nature Communications
Eligible patients were treated with three cycles of neoadjuvant therapy comprising serplulimab, carboplatin, and albumin paclitaxel every 21 days, followed by surgical resection.
